Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
- FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women
- FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
- FDA Approves Zilxi (minocycline) Topical Foam for the Treatment of Rosacea
- FDA Approves Tauvid (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease
News and press releases
- Patients’ and healthcare professionals’ organisations updated on EMA’s response to COVID-19 , , 04/06/2020
- COVID-19: reminder of the risks of chloroquine and hydroxychloroquine , , 29/05/2020
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020, CHMP, 29/05/2020
- New vaccine for prevention of Ebola virus disease recommended for approval in the European Union, CHMP, 29/05/2020
Drugs.com - Clinical Trials
- Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology NEW YORK--(BUSINESS WIRE)...
- Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19 FOSTER CITY,...
- Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus CAMBRIDGE, Mass.--(BUSINESS...
- Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia FOSTER CITY,...
PharmaTimes: PharmaTimes Website RSS
- PharmaTimes talks to...Professor Saad Shakir
- Biogen launches digital self-help tool to support mental health in MS
- NICE publishes final guidance backing Teva's Ajovy for migraine
- AZ, Accent to develop therapies targeting RNA-modifying proteins
- Hydroxychloroquine fails as postexposure prophylaxis for COVID-19